Guidance and quality standards Awaiting development

Showing 1 to 10 of 355

Guidance and quality standards awaiting development
Title	Type
10395 - Aprocitentan for treating resistant hypertension TS ID 10395	Technology appraisal guidance
Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095	Technology appraisal guidance
Abdominal aortic aneurysm	Quality standard
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer TS ID 11831	Technology appraisal guidance
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]	Technology appraisal guidance
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma TS ID 11954	Technology appraisal guidance
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]	Technology appraisal guidance
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia TS ID 11768	Technology appraisal guidance
Acalabrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma TS ID 11823	Technology appraisal guidance
Acne	Quality standard